Status:
COMPLETED
A Double-blind Study to Determine if Intraduodenal Indomethacin Can Decrease the Incidence of Post-ERCP Pancreatitis
Lead Sponsor:
Yale University
Conditions:
Pancreatitis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this research study is to determine if indomethacin, an anti-inflammatory medication in a class of medications known at NSAIDs (non-steroidal anti-inflammatory drugs) can reduce the ris...
Detailed Description
Post-ERCP pancreatitis is likely due to the patient's inflammatory response to duct instrumentation during the procedure and severity is based on the magnitude of this response. Phospholipase A2 (PLA2...
Eligibility Criteria
Inclusion
- Patients undergoing ERCP as part of their clinical care.
Exclusion
- Pancreatitis within 60 days of ERCP
- Age less than 18 years
- Pregnant patients
- Patients who have received NSAIDs within the past 7 days
- Patients with a previous allergy to NSAIDs
- Patients who were previously enrolled in the study
- Patients with a history of peptic ulcers, gastrointestinal bleeding, on anticoagulants and/or with a bleeding diathesis.
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
117 Patients enrolled
Trial Details
Trial ID
NCT00727740
Start Date
August 1 2005
End Date
August 1 2012
Last Update
January 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale New Haven Hospital
New Haven, Connecticut, United States, 06520